Abstract:Objective To explore the correlation between levels of inflammatory factor in peripheral blood and cytokine release syndrome (CRS) in patients with B cell acute lymphoblastic leukemia (B-ALL) after receiving chimeric antigen receptor T cells (CAR-T) immunotherapy.Methods From April 1,2016 to September 30,2018,a total of 38 patients with B-ALL who underwent CAR-T immunotherapy in the Department of Hematology,Affiliated Hospital of Xuzhou Medical University,and had complete clinical data,were selected as subjects.And 21 patients were male and 17 ones were female with median age of 16 years (8-35 years).All patients received the fludarabine combined with cyclophosphamide (FC) conditioning regimen before CAR-T immunotherapy.In this study,all of the 38 patients were treated with humanized CD19 CAR-T (hCART19s),and the total infused number of CAR-T in each patient was calculated as 1 × 106/kg.A retrospective research method was used to collect results of relevant clinical data,laboratory and auxiliary examination.The peak levels of ferritin,C-reactive protein (CRP) and interleukin (IL)-6 in peripheral blood were recorded on d0-30 after CAR-T immunotherapy.According to the clinical data of patients on d0-30 after CAR-T immunotherapy,the CRS of the patients was diagnosed and graded.Correlation analysis between CRS grades and peak levels of ferritin,CRP and IL-6 in peripheral blood was performed using Spearman rank correlation analysis.The Mann-Whitney U test was used to compare the peak levels of ferritin,CRP and IL-6 in peripheral blood between patients with grade 1-2 CRS and grade 3-5 CRS.The procedure followed in this study was in accordance with the ethical standards established by the Human Experimental Committee of the Affiliated Hospital of Xuzhou Medical University,and was approved by the committee (Approval No.XYFY2016-KL002-01).All subjects or their guardians signed an informed consent for this clinical research.Results ① Among the 38 patients with B-ALL in this study,there were 34 patients who developed CRS after CAR-T immunotherapy,and the incidence rate of CRS was 89.5 ％(34/38).There were 24 patients (63.2％) developed grade 1-2 CRS,and 10 cases (26.3％) developed grade 3-5 CRS.The main clinical manifestations of patients with CRS were fever,hypotension,liver or kidney dysfunction,coagulation abnormalities,central nervous system adverse reactions,etc..② The CRS grades of patients with B-ALL after CAR-T immunotherapy were positively correlated with peak levels of ferritin,CRP and IL-6 levels in peripheral blood (rs =0.779,P＜0.001;rs =0.673,P＜0.001;rs =0.612,P＜0.001).③ The median peak levels of peripheral blood ferritin,CRP and IL-6 in patients with grade 3-5 CRS were 33 080 ng/mL (2 352-69 614 ng/mL),200.0 mg/L (151.4-203.5 mg/L) and 799.5 pg/mL (220.9-1 677.5 pg/mL) respectively,which were higher than those of 1 979 ng/mL (1 133-2 147 ng/mL),86.1 mg/L (33.8-136.6 mg/L) and 70.7 pg/mL (18.8-265.2 pg/mL) in patients with grade 1-2 CRS,and the differences were statistically significant (U =210.000,P ＜ 0.001;U =192.000,P =0.005;U =201.000,P =0.001).Conclusions The incidence rate of CRS was high in patients with B-ALL after CAR-T immunotherapy.The severity of CRS was correlated with levels of ferritin,CRP and IL-6 in peripheral blood,and the levels of ferritin,CRP and IL-6 in peripheral blood were significant elevated in patients with severe CRS.Patients with B-ALL need to regularly monitor ferritin,CRP and IL-6 in peripheral blood after CAR-T immunotherapy.When the above inflammatory factors are elevated,it is necessary to be alert to the occurrence of severe CRS.

Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies

Cytokine Release Syndrome in Cancer Immunotherapy with Chimeric Antigen Receptor Engineered T Cells.

Management of Cytokine Release Syndrome Related to CAR-T Cell Therapy

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Tripterygium glycosides as a potential treatment for CAR-T induced cytokine release syndrome: implication of monocyte depletion

CAR-T cell-induced cytokine release syndrome is rapidly alleviated by tripterygium glycosides

Predictive Role of Endothelial Cell Activation in Cytokine Release Syndrome after Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukaemia

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy

Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies

Correlation Analysis Between Levels of Inflammatory Cytokine in Peripheral Blood and Cytokine Release Syndrome in Patients with B-ALL after CAR-T Immunotherapy

Associations of Granulocyte Colony-Stimulating Factor with Toxicities and Efficacy of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory Multiple Myeloma

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective

Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma

[The occurrence of cytokine release syndrome and its impact on the prognosis of patients with relapsed and refractory multiple myeloma following chimeric antigen receptor T-cell therapy]

The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy

Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy

Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies